12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
Simone Perna,1 Manuela Mainardi,2 Paolo Astrone,2 Carlotta Gozzer,3 Anna Biava,1 Ruben Bacchio,3 Daniele Spadaccini,3 Sebastiano Bruno Solerte,2 Mariangela Rondanelli4 1Department of Biology, College of Science, University of Bahrain, Sakhir Campus, Kingdom of Bahrain; 2University of Pavia, Departme...
Saved in:
Main Authors: | Perna S (Author), Mainardi M (Author), Astrone P (Author), Gozzer C (Author), Biava A (Author), Bacchio R (Author), Spadaccini D (Author), Solerte SB (Author), Rondanelli M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incretins and SGLT-2i Therapy of Type 2 Diabetes - Real Life Study of Their Therapeutic and Economic Effects
by: Zornitsa Mitkova, et al.
Published: (2019) -
Sarcopenic obesity: time to target the phenotypes
by: Simone Perna, et al.
Published: (2019) -
Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment
by: Kok-Hou Lok, et al.
Published: (2022) -
The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023) -
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)